Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden.
Nguyen HT, Nguyen N, Liu LY, Dovek L, Lenchner D, Harris R, Ozer B, Ravelo A, Sommer N, Sim MS, Elashoff R, Green R, Nghiemphu PL, Cloughesy TF, Ellingson B, Lai A. Nguyen HT, et al. Among authors: ozer b. Neurooncol Pract. 2019 Mar;6(2):103-111. doi: 10.1093/nop/npy021. Epub 2018 Sep 20. Neurooncol Pract. 2019. PMID: 31386050 Free PMC article.
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A. Nguyen HN, et al. Among authors: ozer b. Neuro Oncol. 2017 Mar 1;19(3):394-404. doi: 10.1093/neuonc/now189. Neuro Oncol. 2017. PMID: 27571882 Free PMC article.
SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
Liu F, Cox CD, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, Prins R, Nghiemphu PL, Yong W, Cloughesy T, Lai A. Liu F, et al. Among authors: ozer b. J Neurooncol. 2019 May;142(3):423-434. doi: 10.1007/s11060-019-03126-x. Epub 2019 Mar 5. J Neurooncol. 2019. PMID: 30838489 Free PMC article.
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.
Rogers JL, Wall T, Acquaye-Mallory AA, Boris L, Kim Y, Aldape K, Quezado MM, Butman JA, Smirniotopoulos JG, Chaudhry H, Tsien CI, Chittiboina P, Zaghloul K, Aboud O, Avgeropoulos NG, Burton EC, Cachia DM, Dixit KS, Drappatz J, Dunbar EM, Forsyth P, Komlodi-Pasztor E, Mandel J, Ozer BH, Lee EQ, Ranjan S, Lukas RV, Raygada M, Salacz ME, Smith-Cohn MA, Snyder J, Soldatos A, Theeler BJ, Widemann BC, Camphausen KA, Heiss JD, Armstrong TS, Gilbert MR, Penas-Prado M. Rogers JL, et al. J Neurooncol. 2024 Apr;167(2):349-359. doi: 10.1007/s11060-024-04613-6. Epub 2024 Mar 1. J Neurooncol. 2024. PMID: 38427131 Free PMC article.
Safety of temozolomide use in adult patients with renal dysfunction.
Garzio K, McElroy K, Grossman S, Holdhoff M, Ozer B, Yankulina O. Garzio K, et al. Among authors: ozer b. J Neurooncol. 2022 Sep;159(3):591-596. doi: 10.1007/s11060-022-04098-1. Epub 2022 Aug 24. J Neurooncol. 2022. PMID: 36001203 Free PMC article.
Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT).
Leeper HE, Tonorezos E, Mayer D, Bakitas M, Chang S, Cooley ME, Hervey-Jumper S, Miaskowski C, Sherwood P, Tsien C, Wallgren K, Willmarth N, Arons D, Acquaye A, King AL, Penas-Prado M, Vera E, Gilbert MR, Armstrong TS; NCI-CONNECT Survivorship Care in Neuro-Oncology Workshop. Leeper HE, et al. Neurooncol Adv. 2022 Feb 28;4(1):vdac029. doi: 10.1093/noajnl/vdac029. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35542753 Free PMC article. Review.
175 results